Enhancement of peroxisomal enzymes, cytochrome P-452 and DNA synthesis in putative preneoplastic foci of rat liver treated with the peroxisome proliferator nafenopin.
The peroxisome proliferator (PP) nafenopin (NAF) enhanced tumor development in rat liver through promotion of a subtype of putative preneoplastic cell foci, characterized by weak cytoplasmic basophilia. In order to elucidate the selective growth advantage of these weakly basophilic foci (WBF) we investigated the effects of NAF on their metabolic phenotype and DNA synthesis. In WBF, as well as in other foci subpopulations and in hepatocellular carcinomas the occurrence of five NAF-inducible enzymes, i.e. of peroxisomal beta-oxidation (acyl-CoA oxidase, bifunctional protein and thiolase), catalase and cytochrome P-452 was studied by immunohistochemical methods. In untreated livers almost all foci were stained with the same intensity as the surrounding tissue. When NAF was applied, most of the liver foci showed considerably less staining than the non-focal parenchyma in which pronounced enzyme induction had occurred. However, the subpopulation of WBF showed a more heterogeneous pattern of enzyme expression varying from less to even more than in the adjacent tissue. A similarly broad range of expression of peroxisomal enzymes was found in hepatocellular carcinomas. On average, however, the tumors exhibited less staining and lower activity of peroxisomal beta-oxidation than the surrounding parenchyma. WBF always showed higher rates of DNA synthesis than other foci subtypes and unaltered liver. In approximately one-third of these foci DNA synthesis was found to be enhanced concomitantly with elevated expression of peroxisomal beta-oxidation enzymes. In conclusion, WBF may have a selective growth advantage as they 'overrespond' to the inducing effects of NAF on DNA synthesis and peroxisomal enzymes.
Grasl-Kraupp
B
B
Institut für Tumorbiologie-Krebsforschung, Universität Wien, Vienna, Austria.
Huber
W
W
Just
W
W
Gibson
G
G
Schulte-Hermann
R
R
D015094:3-Hydroxyacyl CoA Dehydrogenases / Q000302:isolation & purification / Q000378:metabolism; D000101:Acetyl-CoA C-Acetyltransferase / Q000302:isolation & purification / Q000378:metabolism; D042962:Acyl-CoA Oxidase; D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D002374:Catalase / Q000302:isolation & purification / Q000378:metabolism; D003580:Cytochromes / Q000378:metabolism*; D004247:DNA / Q000096:biosynthesis* / Q000187:drug effects; D004261:DNA Replication / Q000187:drug effects*; D004746:Enoyl-CoA Hydratase / Q000302:isolation & purification / Q000378:metabolism; D005260:Female; D015151:Immunoblotting; D007535:Isomerases / Q000302:isolation & purification / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D008830:Microbodies / Q000187:drug effects / Q000201:enzymology*; D009097:Multienzyme Complexes / Q000302:isolation & purification / Q000378:metabolism; D009255:Nafenopin / Q000633:toxicity*; D010088:Oxidoreductases / Q000302:isolation & purification / Q000378:metabolism; D063994:Peroxisomal Bifunctional Enzyme; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar
D002273:Carcinogens; D003580:Cytochromes; D009097:Multienzyme Complexes; D009255:Nafenopin; C046362:cytochrome P-452; D004247:DNA; D010088:Oxidoreductases; D015094:3-Hydroxyacyl CoA Dehydrogenases; D002374:Catalase; D042962:Acyl-CoA Oxidase; D000101:Acetyl-CoA C-Acetyltransferase; D004746:Enoyl-CoA Hydratase; D063994:Peroxisomal Bifunctional Enzyme; D007535:Isomerases